BioSig taps two regional directors to lead its commercial expansion across southeast and central regions of the US

BioSig Technologies Inc (NASDAQ:BSGM), which is commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has added two experienced electrophysiology regional directors to lead its commercial expansion across the southeast and central regions of the US.

The company said Robert Sandler, who will lead regional sales across Texas, brings more than 25 years of sales experience in medical devices. Before joining BioSig, Sandler led regional sales at CardioFocus Inc and Cardiva Medical Inc. And earlier in his career, he was responsible for the Dallas market at Biosense Webster, a Johnson & Johnson company.

In addition, BioSig said Timothy Jones, who was appointed to head regional sales across Florida, has over 20 years of medical equipment sales and sales management experience. Previously, Jones led high-performing commercial teams at CR Bard for Bard Electrophysiology and Bard Access Systems. Most recently, he was employed by Boston Scientific Corp, where he led regional sales for its Augmenix division.

READ: BioSig Technologies announces release of the PURE EP Software Version 4

“We are very pleased to welcome Rob and Tim to our expanding commercial team,” said BioSig CEO Kenneth Londoner in a statement. “Their combined industry expertise, proven track record in medical device sales, and strong relationships in the Texas and Florida electrophysiology markets will allow us to accelerate our commercial sales in these strategically important regions.”

With over 350 electrophysiology labs, BioSig noted that Florida and Texas offer some of the largest clinical footprints in the country.

BioSig’s PURE EP System is currently installed in eight medical centers of excellence across the country, including Mayo Clinic Florida Campus in Jacksonville, Florida, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas, and Houston Methodist Hospital in Houston. 

The company previously announced that it completed commercial sales to St. David’s HealthCare and Mayo Foundation for Medical Education and Research as BioSig expects to triple its customer base in 2021.

BioSig noted that one in 18 Americans suffers from cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the US.

According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the US. each year, resulting in about $6 billion in healthcare spending annually.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Story by ProactiveInvestors